AU Stock MarketDetailed Quotes

OPT Opthea Ltd

Watchlist
  • 0.760
  • +0.035+4.83%
20min DelayNot Open Dec 24 14:10 AET
935.63MMarket Cap-1.47P/E (Static)

About Opthea Ltd Company

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Company Profile

SymbolOPT
Company NameOpthea Ltd
Founded1984
MarketASX
Employees34
Fiscal Year Ends06-30
Address650 Chapel Street Level 4, Suite 0403
CitySouth Yarra
CountryAustralia
Zip Code3141
Phone+61 398260399
Websitehttps://www.opthea.com
Share RegistryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED Yarra Falls, 452 Johnston Street, ABBOTSFORD, VIC, AUSTRALIA, 3067 03 9415 4000

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Frederic Guerard, Pharm.D.
  • Chief Executive Officer
  • 1.32M
  • Peter F. Lang
  • Chief Financial Officer
  • 1.16M
  • Judith J. Robertson
  • Chief Commercial Officer
  • 715.10K
  • Dr. Megan Baldwin
  • Chief Innovation Officer and Executive Director
  • 1.36M
  • Karen Adams
  • Vice President, Finance and Company Secretary
  • 466.17K
  • Julie Clark
  • Senior Vice President, Clinical Development
  • --
  • Dr. John Han
  • Vice President, Medical Affairs
  • --
  • Bruno Gagnon
  • Senior Vice President, Global Clinical Operations
  • --
  • Fang Li, PhD
  • Senior Vice President, Regulatory
  • --
  • Mark O Neill
  • Vice President, Chemistry, Manufacturing and Controls
  • --
  • Kevin Bitter
  • Vice President, Strategy & Corporate Development
  • --
  • Jeremy M. Levin, D.Phil.,M.B.
  • Chairman of the Board
  • 309.43K
  • Dr. Julia A. Haller, M.D.
  • Director
  • 170.25K
  • Anshul Thakral
  • Director
  • 103.72K
  • Lawrence B. Gozlan
  • Independent Director
  • 790.52K
  • Sujal Shah
  • Independent Director
  • 16.72K
  • Susan Orr
  • Independent Director
  • 130.26K
  • Quinton Oswald
  • Independent Director
  • 135.81K
Heat List
AU
Overall
Symbol
Price
% Chg

No Data